Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Share-based Compensation (2016 - 2021)

GT Biopharma (GTBP) has disclosed Share-based Compensation for 12 consecutive years, with $9.8 million as the latest value for Q1 2021.

  • On a quarterly basis, Share-based Compensation changed N/A to $9.8 million in Q1 2021 year-over-year; TTM through Mar 2021 was $10.1 million, a 267.34% increase, with the full-year FY2025 number at $432000.0, up 87.83% from a year prior.
  • Share-based Compensation was $9.8 million for Q1 2021 at GT Biopharma, up from $269000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $124.4 million in Q3 2017 to a low of -$894000.0 in Q4 2019.
  • A 5-year average of $11.4 million and a median of $1.1 million in 2019 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: skyrocketed 6963.09% in 2017, then tumbled 105.89% in 2020.
  • GT Biopharma's Share-based Compensation stood at $4.2 million in 2017, then decreased by 27.47% to $3.1 million in 2018, then tumbled by 129.22% to -$894000.0 in 2019, then soared by 130.09% to $269000.0 in 2020, then surged by 3545.72% to $9.8 million in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Share-based Compensation are $9.8 million (Q1 2021), $269000.0 (Q4 2020), and -$147000.0 (Q3 2020).